Crohn’s Disease (CD) Treatment Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Are the Primary Drivers Supporting the Market Growth of theCrohn’s Disease (CD) Treatment Market?
The escalating occurrence of inflammatory bowel diseases is predicted to be a factor contributing to the growth of the Crohn’s disease (CD) treatment market. Inflammatory bowel disease (IBD) consists of a range of chronic inflammatory disorders predominantly impacting the gastrointestinal (GI) tract. Treatments for Crohn’s disease (CD) offer symptom relief, reduce inflammation, push the disease into remission, and improve the overall quality of life for those with the chronic condition. For example, the United States National Library of Medicine mentioned in September 2023 that IBD incidence in Canada was estimated to be 30 out of every 100,000 person-years in 2023, projecting a mild yearly rise of approximately 0.58%. As of 2023, the IBD prevalence in Canada had reached around 825 per 100,000, with predictions indicating this could soar to 1.1% of the population by 2035. As a result, the rising occurrence of IBD is propelling the Crohn’s disease (CD) treatment market. Elevated clinical trial numbers are expected to boost the Crohn’s disease treatment market. Clinical trials are necessary to ascertain the safety and effectiveness of new therapies, with successful trials potentially leading to regulatory approvals and subsequent introduction of novel treatments for CD. The need for more effective treatments for Crohn’s disease is driving clinical trials in response to patients and healthcare providers’ fervent desire for improved outcomes with minimal side effects, thereby spurring research and development initiatives. For example, the University of California stated in September 2023 that there are currently 17 ongoing clinical trials at UCSF focusing on the use of vedolizumab and oral ozanimod. These trials are aimed at evaluating the long-term effectiveness of mirikizumab in pediatric patients suffering from Crohn’s disease or ulcerative colitis. Hence, increased clinical trial activity is anticipated to stimulate the Crohn’s disease treatment market’s expansion.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12902&type=smp
How Has the Crohn’s Disease (CD) Treatment Market Evolved in Recent Years, and What are the Growth Projections for the Forecast Period?
There has been a significant growth in the market size for the treatment of Crohn’s Disease (CD) in the last few years. This market is expected to increase from $11.76 billion in 2024 to $12.38 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.3%. The growth experienced in the previous years can be linked to the increasing cases of Crohn’s disease, heightened awareness about the illness, initiatives by the government and changing lifestyle trends.
Expectations are high for the Crohn’s disease (CD) treatment market, with predictions of a robust growth trajectory in the coming years. The market size is anticipated to reach $15.06 billion in 2029, expanding at a compound annual growth rate (CAGR) of 5.0%. Factors such as a rising need for combination treatments, broader acceptance of biologics, and increased investment in CD research and development are contributing to this forecasted growth. Key market trends to watch include the development of biological drugs, groundbreaking products, cutting-edge diagnostic tools, and a wider embrace of biosimilars.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12902
What Are the Latest Innovations Influencing theCrohn’s Disease (CD) Treatment Market?
Key players in the treatment market for Crohn’s disease (CD) are integrating innovative technologies like IBDSENSE to maintain their market dominance. As an example, the IRR Chemistry Hub, headquartered in Scotland, rolled out IBDSENSE in March 2023. The core intent of this technology is to enhance the diagnosis and oversight of inflammatory bowel disease with non-disruptive methods, Crohn’s disease included. The project relies on a fluorescence-based technology to assess the enzymatic activity of Granzyme B (GzmB) in the biosamples of patients. Through this technology, the goal is to refine the patient experience and expand treatment options.
Who Are the Major Industry Players Accelerating Growth in theCrohn’s Disease (CD) Treatment Market?
Major companies operating in the crohn’s disease (cd) treatment market are Pfizer Inc., Johnson and Johnson Ltd., Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC.
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report
Which Primary Segments of the Crohn’s Disease (CD) Treatment Market Are Driving Growth and Industry Transformations?
The crohn’s disease (CD) treatment market covered in this report is segmented –
1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types
2) By Route of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores
Subsegments:
1) By Antibiotics: Metronidazole, Ciprofloxacin, Rifaximin
2) By Amino Salicylates: Mesalamine, Sulfasalazine
3) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
4) By Immunomodulators: Azathioprine, Mercaptopurine, Methotrexate
5) By Other Drug Types: Biologic Therapies, Janus Kinase Inhibitors, Small Molecules
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12902&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theCrohn’s Disease (CD) Treatment Market?# Market?
North America was the largest region in the Crohn’s disease (CD) treatment market in 2024. The regions covered in Crohn’s disease (CD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Reports Similar to the Global Crohn’s Disease (CD) Treatment Market 2025, By The Business Research Company:
Gastric Cancer Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report
Gastric Volvulus Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report
Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
